Anastasia Constantinidou

TL;DR: This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1‐ PDL‐1 inhibitors in the corresponding cancer types and presents available data on the combinations of PD1 • PDL •1 inhibitors with other therapies, the toxicity profile of the PD1• PDL•1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already.

TL;DR: This review critically assesses the current cervical cancer screening methods as well as the implementation of HPV vaccination in Europe and the most recent European Guidelines and recommendations for organized population-based programs with HPV testing as the primary screening method are presented.

TL;DR: The current knowledge on midkine expression and function in cancer development and progression is summarized, and its promising potential as a cancer biomarker and as a future therapeutic target in personalized cancer medicine is highlighted.

TL;DR: PLD as a single agent therapy has acceptable toxicity and highly promising activity in unresectable AF and may provide long-term clinical benefit in some patients.

TL;DR: Thorough understanding of the prognostic and predictive relevance of different genetic subtypes of GIST can guide clinical decision-making both in the adjuvant and the metastatic setting and to identify predictive factors of resistance to currently approved systemic therapies.